The Oxford Vaccine Group’s director, Andrew Pollard, mentioned in a media briefing there have been “lots of cases” of infections in its Phase III trial in Britain, Brazil and South Africa.
The first two units of interim information from vaccine trials from Pfizer and BioNTech final week and Moderna on Monday had been launched after greater than 90 infections amongst volunteers.
Pfizer had deliberate to publish preliminary information after about 60 infections, but it surely exceeded its goal after the large soar in infections lately within the United States.
Pollard’s feedback got here after information printed on Thursday confirmed the Oxford/AstraZeneca vaccine in Phase II research produced a robust immune response in older adults, suggesting that these at greater danger of significant sickness and death from Covid-19 could possibly be protected.
Pollard mentioned there was no try to launch the research in the identical week as these corporations’ information, the primary from late-stage vaccine trials, however moderately the research occurred to be prepared for publication.
Earlier on Thursday, he mentioned he anticipated Phase III information to be launched by Christmas.
The Phase III outcomes displaying efficacy of the vaccine will probably be launched by way of AstraZeneca, in the identical manner they’ve been printed by different drugmakers over the previous week or so, Pollard mentioned.
He mentioned the trial would additionally publish the findings in a peer-reviewed medical journal however preliminary information would possible be launched earlier than then.